Article Text

Download PDFPDF
842 Outcomes in mucinous ovarian/fallopian tube cancer (MOC); real world outcomes from two tertiary London centres
  1. Angel Luis Orosco-Ttamina1,
  2. Uma Mukherjee1,
  3. Shanthini Mary Crusz2,
  4. Mary Mccormack1,
  5. Michael Flynn1,
  6. Melanie Powell2,
  7. Michelle Lockley1,3,
  8. Shibani Nicum1,
  9. Rowan Elizabeth Rowan1,3 and
  10. Michael-John Devlin2,3
  1. 1Oncology Department, University College London Hospital, London, UK
  2. 2Oncology Department, St Bartholomew’s Hospital, London, UK
  3. 3Barts Cancer Institute, Queen Mary University of London, London, UK


Introduction/Background MOC is a rare form of epithelial ovarian cancer, most frequently presenting at an early stage. We investigated real-world outcomes in this rare pathology across two tertiary centres.

Methodology Patients with a diagnosis of MOC treated at University College London and St Bartholomew’s Hospitals between 2009–2021 were identified and data collected. Calculations were performed using Prism v9.5.1; p=<0.05 was considered significant.

Results 90 patients were identified; FIGO I n=67 (75%), II n=12 (13%), III n=9 (10%), IV n=1 (1%); unknown n=1 (1%). Tumour grade(G)1 n=24 (27%), G2 n=43 (48%) and G3 n=11 (12%); unknown n=2 (2%). Median age 51 years (21–97); 88/90 (98%) had primary surgery; 2/90 (2%) inoperable. 51 patients had documented appendectomy; 1/51 (2%) with serosal involvement. 33 patients had systemic anti-cancer therapy (SACT); carboplatin/paclitaxel n=26 (79%); single agent carboplatin n=3 (10%) and FOLFOX/CAPOX n=4 (12%). Long term survival data available for 88 patients; 2 lost to follow-up. Relapse rate (RR); FIGO I 10/65 (15%), II 1/12 (8%), III 8/9 (89%) and IV 1/1 (100%). RR for FIGO I G3 was 3/6 (50%), significantly higher (p=0.0072) compared to G1 1/28 (4%) but not G2 disease 6/32 (19%). 9/61 (15%) FIGO I G1/G2 disease received SACT with no significant difference in RR p=0.06. For FIGO I/II disease, median progression free survival (mPFS) and overall survival (mOS) not reached; III mPFS 10 months and mOS 33 months; IV mPFS 6 months and OS 6months.

Conclusion We found MOC most frequently presented with FIGO I/II disease which, alongside tumour grade, inferred a better prognosis. We found no benefit from SACT in reducing relapse in early-stage low grade tumours. Patients with advanced stage disease are likely to recur with a short mPFS and mOS reflecting the need for further research to SACT options in this population.

Disclosures See attached COI forms.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.